{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:02:54Z","timestamp":1792699374995,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100003887","name":"International Myeloma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50CA186781"],"award-info":[{"award-number":["P50CA186781"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.hoc.2023.12.010","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T09:17:55Z","timestamp":1704791875000},"page":"267-279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Molecular Pathogenesis of Multiple Myeloma"],"prefix":"10.1016","volume":"38","author":[{"given":"Francesco","family":"Maura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Leif","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.hoc.2023.12.010_bib1","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"24","key":"10.1016\/j.hoc.2023.12.010_bib2","doi-asserted-by":"crossref","first-page":"13931","DOI":"10.1073\/pnas.93.24.13931","article-title":"Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma","volume":"93","author":"Bergsagel","year":"1996","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.010_bib3","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.010_bib4","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.010_bib5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.hoc.2023.12.010_bib6","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2023.12.010_bib7","unstructured":"ACS. Cancer Statistics Center. 2023; Available at: https:\/\/cancerstatisticscenter.cancer.org\/#!\/cancer-site\/Myeloma. Accessed June 19, 2023."},{"issue":"4","key":"10.1016\/j.hoc.2023.12.010_bib8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/leu.2011.368","article-title":"Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites","volume":"26","author":"Greenberg","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.010_bib9","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2014.34","article-title":"Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey","volume":"28","author":"Landgren","year":"2014","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.hoc.2023.12.010_bib10","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2023.12.010_bib11","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A\u00a0monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.010_bib12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.010_bib13","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41467-020-15740-9","article-title":"Timing the initiation of multiple myeloma","volume":"11","author":"Rustad","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.010_bib14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.V88.2.674.bloodjournal882674","article-title":"Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines","volume":"88","author":"Chesi","year":"1996","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.010_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V98.1.217","article-title":"Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma","volume":"98","author":"Shaughnessy","year":"2001","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2023.12.010_bib16","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood.2022015854","article-title":"Genomic profiling for clinical decision making in lymphoid neoplasms","volume":"140","author":"de Leval","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.010_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41408-020-0294-5","article-title":"The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias","volume":"10","author":"Baughn","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.010_bib18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/0008-5472.BCD-19-0068","article-title":"Monosomic loss of MIR15A\/MIR16-1 is a driver of multiple myeloma proliferation and disease progression","volume":"1","author":"Chesi","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.010_bib19","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3324\/haematol.13369","article-title":"Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis","volume":"94","author":"Bryce","year":"2009","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.010_bib20","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","article-title":"Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients","volume":"99","author":"Fonseca","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.010_bib21","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2023.12.010_bib22","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","article-title":"Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance","volume":"115","author":"Nair","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.010_bib23","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1182\/blood-2019-131870","article-title":"Long-term outcome of total therapy regimens: impact of molecular subgroups","volume":"134","author":"van Rhee","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.010_bib24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.hoc.2023.12.010_bib25","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.010_bib26","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood.V91.12.4457.412k48_4457_4463","article-title":"Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma","volume":"91","author":"Chesi","year":"1998","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.010_bib27","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood-2010-07-295105","article-title":"Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?","volume":"117","author":"Avet-Loiseau","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.010_bib28","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.010_bib29","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2017.345","article-title":"Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines","volume":"32","author":"Maura","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.010_bib30","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/leu.2015.309","article-title":"Clinical value of molecular subtyping multiple myeloma using gene expression profiling","volume":"30","author":"Weinhold","year":"2016","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.hoc.2023.12.010_bib31","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1182\/blood-2016-03-706077","article-title":"MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma","volume":"128","author":"Qiang","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.010_bib32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1535-6108(04)00019-4","article-title":"Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma","volume":"5","author":"Hurt","year":"2004","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.010_bib33","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/ng0797-260","article-title":"Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3","volume":"16","author":"Chesi","year":"1997","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.010_bib34","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood.V92.9.3025","article-title":"The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH\/MMSET hybrid transcripts","volume":"92","author":"Chesi","year":"1998","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.010_bib35","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.molcel.2011.08.042","article-title":"NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming","volume":"44","author":"Kuo","year":"2011","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.010_bib36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2010-07-298349","article-title":"The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells","volume":"117","author":"Martinez-Garcia","year":"2011","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.hoc.2023.12.010_bib37","doi-asserted-by":"crossref","first-page":"51608","DOI":"10.18632\/oncotarget.18209","article-title":"MB4-2\/MB4-3 transcripts of IGH-MMSET fusion gene in t(4;14)(pos) multiple myeloma indicate poor prognosis","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.hoc.2023.12.010_bib38","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood.2022016212","article-title":"The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM","volume":"141","author":"Stong","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.010_bib39","first-page":"3027","article-title":"FGFR3 mutations are an adverse prognostic factor in patients with t (4; 14)(p16; q32) multiple myeloma: an Mmrf commpass analysis","volume":"130","author":"Benard","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.010_bib40","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/ejh.12491","article-title":"Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation","volume":"95","author":"Scheid","year":"2015","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.010_bib41","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a006249","article-title":"Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression","volume":"9","author":"Croucher","year":"2023","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.010_bib42","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.010_bib43","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","article-title":"MYC dysregulation in the progression of multiple myeloma","volume":"34","author":"Misund","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.010_bib44","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41467-019-09555-6","article-title":"Multiple myeloma immunoglobulin lambda translocations portend poor prognosis","volume":"10","author":"Barwick","year":"2019","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.010_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/genes8060151","article-title":"MYC Deregulation in Primary Human Cancers","volume":"8","author":"Kalkat","year":"2017","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.010_bib46","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41467-020-20524-2","article-title":"The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma","volume":"12","author":"Boyle","year":"2021","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.010_bib47","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.010_bib48","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/jha2.8","article-title":"RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation","volume":"1","author":"Le Calvez","year":"2020","journal-title":"EJHaem"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.010_bib49","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1038\/s41467-022-33142-x","article-title":"Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma","volume":"13","author":"Yang","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.010_bib50","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.010_bib51","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1073\/pnas.97.8.3919","article-title":"Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell","volume":"97","author":"De Bosscher","year":"2000","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.010_bib52","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.molcel.2012.10.013","article-title":"Insights into negative regulation by the glucocorticoid receptor from genome-wide profiling of inflammatory cistromes","volume":"49","author":"Uhlenhaut","year":"2013","journal-title":"Mol Cell"},{"issue":"26","key":"10.1016\/j.hoc.2023.12.010_bib53","doi-asserted-by":"crossref","first-page":"15671","DOI":"10.1073\/pnas.95.26.15671","article-title":"Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis","volume":"95","author":"Palombella","year":"1998","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"22","key":"10.1016\/j.hoc.2023.12.010_bib54","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1200\/JCO.21.00972","article-title":"Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.010_bib55","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/ejh.13435","article-title":"Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-kappaB pathway activation","volume":"105","author":"Dash","year":"2020","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.010_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188449","article-title":"Pharmacological significance of the non-canonical NF-kappaB pathway in tumorigenesis","volume":"1874","author":"Morgan","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.010_bib57","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2023.12.010_bib58","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1747-1028-1-23","article-title":"Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression","volume":"1","author":"Dib","year":"2006","journal-title":"Cell Div"},{"issue":"15","key":"10.1016\/j.hoc.2023.12.010_bib59","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","article-title":"A\u00a0compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.010_bib60","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.010_bib61","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1182\/blood-2003-10-3399","article-title":"Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies","volume":"103","author":"Linden","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.010_bib62","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1182\/blood-2006-07-038703","article-title":"CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.010_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112047","article-title":"RNA exosome ribonuclease DIS3 degrades Pou6f1 to promote mouse pre-implantation cell differentiation","volume":"42","author":"Wu","year":"2023","journal-title":"Cell Rep"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.010_bib64","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.2020008346","article-title":"del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:18:48Z","timestamp":1760591928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823001776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0889858823001776"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.010","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Pathogenesis of Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}